STAAR Surgical (STAA) Stock Overview
Designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for STAA from our risk checks.
STAA Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
STAAR Surgical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.11 |
| 52 Week High | US$35.87 |
| 52 Week Low | US$15.59 |
| Beta | 1.23 |
| 1 Month Change | -13.24% |
| 3 Month Change | -13.12% |
| 1 Year Change | -10.77% |
| 3 Year Change | -48.47% |
| 5 Year Change | -83.18% |
| Change since IPO | 1.52% |
Recent News & Updates
Narrative Update • Jul 29
STAA: Sector Procedure Risks And China Uncertainty Will Limit Future Upside
The analyst fair value estimate for STAAR Surgical has moved from $23.00 to $20.00, reflecting the new $20 UBS price target and more cautious assumptions, despite generally supportive comments on recent Q1 trends from other firms. Analyst Commentary Recent research on STAAR Surgical reflects a wide range of opinions, with some firms highlighting strong Q1 execution and others leaning more cautious on growth durability and valuation.Seeking Alpha • Jul 17
STAAR Surgical's Punishment For Opacity Is Just
Summary STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance. I maintain a Sell rating on STAA stock, pending more substantive guidance at the August 12th earnings release to assess if recent gains are sustainable. Read the full article on Seeking AlphaNarrative Update • Jun 30
STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence
The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.Analysis Article • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...Recent updates
Narrative Update • Jul 29
STAA: Sector Procedure Risks And China Uncertainty Will Limit Future Upside
The analyst fair value estimate for STAAR Surgical has moved from $23.00 to $20.00, reflecting the new $20 UBS price target and more cautious assumptions, despite generally supportive comments on recent Q1 trends from other firms. Analyst Commentary Recent research on STAAR Surgical reflects a wide range of opinions, with some firms highlighting strong Q1 execution and others leaning more cautious on growth durability and valuation.Seeking Alpha • Jul 17
STAAR Surgical's Punishment For Opacity Is Just
Summary STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance. I maintain a Sell rating on STAA stock, pending more substantive guidance at the August 12th earnings release to assess if recent gains are sustainable. Read the full article on Seeking AlphaNarrative Update • Jun 30
STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence
The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.Analysis Article • Jun 16
STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple
Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...
Narrative Update • Jun 16
STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating
STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.
Narrative Update • Jun 02
STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment
The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.Narrative Update • May 15
STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance
Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.Narrative Update • Apr 20
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.Narrative Update • Apr 06
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.Narrative Update • Mar 23
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.Narrative Update • Mar 09
STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.Narrative Update • Feb 23
STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.Narrative Update • Feb 08
STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.Narrative Update • Jan 25
STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.Narrative Update • Jan 10
STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.Narrative Update • Dec 26
STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.Narrative Update • Dec 12
STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.Narrative Update • Nov 28
STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.Narrative Update • Nov 12
STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Narrative Update • Oct 29
Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Narrative Update • Oct 15
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Narrative Update • Aug 20
Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Narrative Update • Aug 06
Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Analysis Article • Jul 04
Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...Analysis Article • Apr 05
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Feb 14
Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...Seeking Alpha • Feb 12
STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking AlphaAnalysis Article • Nov 29
STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Analysis Article • Oct 24
Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
New Narrative • Sep 13
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.Seeking Alpha • Sep 05
STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Summary STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets. I have a price target of $46 by 2026, which represents an attractive upside from today’s level. Read the full article on Seeking AlphaAnalysis Article • Aug 10
Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
STAAR Surgical Company ( NASDAQ:STAA ) investors will be delighted, with the company turning in some strong numbers...Analysis Article • Aug 05
STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Analysis Article • Jul 12
The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Shareholder Returns
| STAA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.4% | 2.3% | 2.4% |
| 1Y | -10.8% | -12.8% | 19.6% |
Return vs Industry: STAA exceeded the US Medical Equipment industry which returned -16.1% over the past year.
Return vs Market: STAA underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| STAA volatility | |
|---|---|
| STAA Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STAA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STAA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 921 | Deborah Andrews | www.staar.com |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.
STAAR Surgical Company Fundamentals Summary
| STAA fundamental statistics | |
|---|---|
| Market cap | US$1.21b |
| Earnings (TTM) | -US$21.03m |
| Revenue (TTM) | US$290.38m |
4.1x
P/S Ratio-57.1x
P/E RatioIs STAA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STAA income statement (TTM) | |
|---|---|
| Revenue | US$290.38m |
| Cost of Revenue | US$67.10m |
| Gross Profit | US$223.27m |
| Other Expenses | US$244.31m |
| Earnings | -US$21.03m |
Last Reported Earnings
Apr 03, 2026
Next Earnings Date
Aug 12, 2026
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 76.89% |
| Net Profit Margin | -7.24% |
| Debt/Equity Ratio | 0% |
How did STAA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 23:22 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/04/03 |
| Annual Earnings | 2026/01/02 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STAAR Surgical Company is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |